
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics Inc demonstrates a strong positive outlook due to the successful topline results from pivotal Phase 3 trials of its lead asset, phentolamine, in treating presbyopia and keratorefractive surgery patients, indicating a significant gain in visual acuity. The planned submission of a supplemental New Drug Application (sNDA) in the second half of 2025 for presbyopia reinforces the trajectory of potential market entry and revenue generation. The strategic collaboration with Viatris for the commercialization of phentolamine further supports the company’s financial stability and growth prospects in addressing a broad range of retinal and refractive disorders.
Bears say
Opus Genetics faces significant risks that contribute to a negative outlook, primarily due to the uncertainty surrounding the commercial viability of its product candidates, which may not achieve projected peak revenue estimates influenced by market size and penetration rates. Additionally, the company's financial stability may be jeopardized if it fails to secure sufficient capital resources to sustain its operations, impacting ongoing product development and commercialization efforts. Lastly, potential competitive pressures and safety concerns raised by similar products from other companies may hinder Opus Genetics' ability to effectively penetrate the market.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares